Drug,CMML Subtype,Complete Response (CR),Partial Response (PR),Marrow CR / Optimal,PFS (median),OS (median),SAEs (%)
Azacitidine,Overall,12.5%,62.5%,...,...,36.0 months,...
,RAS-mutant,...,...,...,...,...,...
,Non-RAS-mutant,...,...,...,...,...,...
Decitabine,Overall,7.0%,11.0%,...,...,36.0 months,...
,RAS-mutant,...,...,...,...,...,...
,Non-RAS-mutant,...,...,...,...,...,...
Hydroxyurea,Overall,...,...,...,...,24.0 months,...
,RAS-mutant,...,...,...,...,...,...
,Non-RAS-mutant,...,...,...,...,...,...
